Power Law company profile

Adaptimmune

Biotech & Life Sciences · Milton, United Kingdom · Founded 2008 · IPO 2015 Unicorn

Engineered T-cell receptor therapies for solid tumors

Valuation

$57M

Market cap · 2026

Revenue

$178M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

13 investors on Adaptimmune's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 11 investors entered at this stage

Merlin Nexus

MPM BioImpact

Rock Springs Capital

Foresite Capital

Novo Holdings

NEA

OrbiMed

Ridgeback Capital

Wellington Management

F-Prime

venBio Partners

Series B+ 2 investors entered at this stage

University of Oxford

Oxford University Innovation

Global footprint

Where Adaptimmune has talent and traffic

Workforce by country

8 countries with
team presence

🇺🇸 United States55.5%

🇬🇧 United Kingdom43.2%

🇦🇺 Australia0.4%

🇮🇪 Ireland0.3%

🇪🇸 Spain0.3%

Top 5 of 8 shown

Web traffic by country

7.5K monthly visits
across markets

🇺🇸 United States45.3%

🇬🇧 United Kingdom32%

🇮🇳 India13.3%

🇨🇦 Canada5.3%

🇯🇵 Japan2.7%

Top 5 markets shown

Market sentiment

What the market is saying about Adaptimmune

An AI-synthesized read of the highest-engagement posts about Adaptimmune on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Adaptimmune on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles